Press releases

New Advancements Enable Lipid Imaging and Quantification for Diabetes and Metabolic Syndrome Drug Development and Diagnostic

Washington D.C., June 9, 2006 - QuantomiX Ltd., a leading provider of innovative bio-medical diagnostic imaging modalities, will be presenting LipidSCAN^TM, its proprietary solution for lipid imaging and quantification based on QuantomiX' WETSEM^TM technology, at the ADA's 66th Annual Scientific Session in Washington D.C. This breakthrough technology is especially relevant for members of the American Diabetes Association, for whom the study of obesity, diabetes, and other metabolic disorders is paramount.

Lipid accumulation plays a key role in diabetes and metabolic syndrome. Using QuantomiX technology, researchers and clinicians can now gain insight into diabetes and obesity diseases with comprehensive and reliable images and data, revealing lipid deposition and accumulation at the sub-cellular level in tissues and white blood cells. Leaders in the field expect QuantomiX technology to improve drug development and enable early diagnosis of diabetes and other metabolic disorders.

"QuantomiX LipidSCAN^TM allows us to ask important medical research questions we couldn't ask before this technology was available and opens up a whole set of parameters we couldn´t measure before, such as lipid droplet size, the spatial alignment of mitochondria and lipid droplets and this relationship in metabolic disease," according to David Kelley, M.D., Professor of Medicine and Director of Obesity & Nutrition Research Center, University of Pittsburgh School of Medicine, who is using QuantomiX LipidSCAN^TM in his research.

"Seeing lipid deposits in Beta cells is a new capability made possible by QuantomiX and is something that has been validated by this technology," according to Dr. Barbara Corkey, Ph.D., Professor of Medicine & Biochemistry and Director, Obesity Research Center, Boston University School of Medicine, who has also been using QuantomiX LipidSCAN^TM in her research.

QuantomiX current focus is to provide lipid imaging and analysis to leading U.S. and European pharmaceutical companies and CROs for metabolic diseases drug efficacy and toxicity studies. The Company is also developing its technology for use in medical diagnostics for diabetes and other diseases.

QuantomiX will be presenting its LipidSCAN^TM technology at an ADA scientific poster session entitled "Imaging and Quantitative Analysis of Lipid Accumulation in Different Organs in a Mouse Model of Type 2 Diabetes" (Poster 1678-P) on Sunday June 11 from 12:00-2:00PM in the Main Exhibit Hall as well as at the company's exhibit booth.

About QuantomiX

QuantomiX develops and markets breakthrough bio-medical imaging solutions based on its proprietary WETSEM^TM technology, which for the first time enables high resolution imaging of wet samples. This technology provides new opportunities to speed drug discovery and development, and advance treatment and diagnostic solutions for the medical and pharmaceutical markets.